Format

Send to

Choose Destination
QJM. 2014 Jan;107(1):7-14. doi: 10.1093/qjmed/hct116. Epub 2013 Jun 5.

Leishmaniasis: clinical syndromes and treatment.

Author information

1
Division of Infectious Diseases, Department of Internal Medicine, The Ohio State University, Doan N1145, 410 W. 10th Ave., Columbus, OH 43210, USA. brad.mcgwire@osumc.edu.

Abstract

Leishmaniasis is a global term for cutaneous and visceral anthroponotic and zoonotic diseases caused by the vector-borne parasites of the genus Leishmania. These diseases afflict at least 2 million people each year with more than 350 million at risk in 98 countries worldwide. These are diseases mostly of the impoverished making prevention, diagnosis and treatment difficult. Therapy of leishmaniasis ranges from local treatment of cutaneous lesions to systemic, often toxic, therapy for disseminated cutaneous, mucocutaneous and deadly visceral disease. This review is a summary of the clinical syndromes caused by Leishmania and treatment regimens currently used for various forms of leishmaniasis.

PMID:
23744570
PMCID:
PMC3869292
DOI:
10.1093/qjmed/hct116
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center